Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2020-06-14 Investor Presentation
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Avecho Investor Update 25 pages 1.1MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated 15 June 2020 from Avecho Biotechnology Limited. It is titled 'Avecho Investor Update' and includes detailed information about the company's business, management, technology, strategic focus, and product pipeline. It mentions a virtual presentation for investors and analysts scheduled for 19 June 2020 and includes a link to register for the webinar. The content is structured as a presentation with slides and detailed company information, focusing on financials, strategy, and market position. There are no full financial statements or comprehensive financial performance data typical of annual or interim reports. The document is not a regulatory filing, certification, or voting result announcement. It is clearly an investor presentation intended to inform investors and analysts about the company's current status and outlook. Therefore, the most appropriate classification is Investor Presentation (IP).
2020-06-14 English
Notice of Annual General Meeting/Proxy Form 18 pages 490.8KB
AGM Information Classification · 95% confidence The document is titled 'Notice of Annual General Meeting Explanatory Statement and Proxy Form' and details the date, time, and procedures for the AGM of Avecho Biotechnology Limited. It includes the agenda, resolutions to be voted on, proxy voting instructions, and other meeting logistics. The content is focused on informing shareholders about the AGM and facilitating their participation and voting. There is no financial data or report content itself, but rather the notice and explanatory materials related to the AGM. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting. The document length is substantial but it is clearly a notice and explanatory statement for the AGM, not the annual report or other filings. Therefore, the correct classification is AGM-R with high confidence.
2020-06-10 English
Date of AGM and Closing Date for Nomination of Director 1
AGM Information Classification · 95% confidence The document is an ASX announcement dated 18 May 2020 regarding the date of the upcoming Annual General Meeting (AGM) and the closing date for director nominations. It references the AGM date and nomination deadline but does not contain any AGM materials, minutes, or voting results. It is a notice about the AGM scheduling and director nomination process. The document length is short (2494 characters), and it serves as an announcement rather than the AGM report or materials themselves. Therefore, it fits best under the category of AGM Information announcements related to the AGM event.
2020-05-17 English
March 2020 Quarterly Activities Report & Appendix 4C 7 pages 99.7KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement dated 29 April 2020, titled 'Avecho Quarterly Activities Report and Appendix 4C' for the quarter ended 31 March 2020. It contains detailed operational updates, cash flow statements, and financial data for the quarter, including cash flows from operating, investing, and financing activities, as well as management changes. The presence of Appendix 4C, which is a quarterly cash flow report required by ASX Listing Rule 4.7B, confirms this is a quarterly report with substantive financial data and analysis. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-04-28 English
Medicinal cannabis supply agreement with Tasmanian Alkaloids 2 pages 101.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 27 April 2020 from Avecho Biotechnology Limited. It announces a new medicinal cannabis supply agreement with Tasmanian Alkaloids. The content focuses on the details of the supply agreement, the strategic rationale, and quotes from company executives. There are no financial statements, no quarterly or annual results, no voting results, no management changes, no legal proceedings, and no regulatory certifications. The document is a corporate announcement about a commercial agreement, which fits the category of Capital/Financing Update (CAP) as it relates to supply agreements and commercial arrangements that impact the company's operations and potential future revenues. The document length is 5565 characters, which is consistent with a detailed announcement but not a full report. Therefore, the best classification is CAP with high confidence.
2020-04-26 English
Changes to Leadership Team 3 pages 90.0KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 27 April 2020 regarding changes to the leadership team of Avecho Biotechnology Limited. It details the appointment of a new CEO and COO, including their backgrounds and terms of appointment. The document does not contain financial statements, quarterly or annual results, or detailed financial analysis. It is a formal announcement about management changes, which fits the category of Board/Management Information (MANG). The document length is 6362 characters, which is sufficient for a detailed announcement but does not constitute a full report. There is no indication that this is a report or presentation, nor is it a regulatory filing or certification. Therefore, the appropriate classification is MANG with high confidence.
2020-04-26 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.